MaxCyte (LON:MXCT) Sets New 52-Week Low - Should You Sell?

MaxCyte, Inc. (LON:MXCT - Get Free Report)'s share price hit a new 52-week low on Thursday . The stock traded as low as GBX 200 ($2.60) and last traded at GBX 205.68 ($2.67), with a volume of 26796 shares. The stock had previously closed at GBX 213 ($2.77).MaxCyte Trading Down 3.4 %The company has a current ratio of 9.81, a quick ratio of 14.38 and a debt-to-equity ratio of 8.59. The firm has a market capitalization of £271.51 million, a price-to-earnings ratio of -7.54 and a beta of 1.13. The company has a fifty day moving average price of GBX 294.19 and a two-hundred day moving average price of GBX 302.57. About MaxCyte (Get Free Report)MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.Recommended StoriesFive stocks we like better than MaxCyte3 Warren Buffett Stocks to Buy NowShares of RH Down Nearly 40%: Where Investors Can Turn To NowETF Screener: Uses and Step-by-Step Guide Tariffs, Spin-Out, and R2 Updates Are Positive Signs for RivianThe Top 3 Healthcare Dividend Stocks to Buy and HoldCathie Wood Loads Up on Baidu—Is It the Right Time to Buy?This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in MaxCyte Right Now?Before you consider MaxCyte, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here